Protocol H8H- CD-LAHH   
 
 
A PHASE 1 STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND 
EXCRETION OF [14C] -LASMIDITAN FOLLOWING SINGLE ORAL DOSE 
ADMINISTRATION IN HEALTHY MALE AND FEMALE SUBJECTS  
 
[STUDY_ID_REMOVED] 
 Approval Date: 23- Jan-2017
 
 
 
 
Clinical Study Report  
CoLucid Reference: COL MIG -110 
  CONFIDENTIAL   
16.1.1 Protocol and Amendment s 
Final
Page 1 of 49
Approval Date: 26-Mar-2018 GMT
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 1 of 48 
 A PHASE 1 STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, 
AND EXCRETION OF [14C]-LASMIDITAN FOLLOWING SINGLE ORAL 
DOSE ADMINISTRATION IN HEALTHY MALE AND FEMALE SUBJECTS  
 
  
 
Protocol COL MIG -110 
 
Covance Study 8331469 
 
IND 103,420 
   
for 
 
CoLucid Pharmaceuticals, Inc.  
222 Third Street, Suite 1320 
Cambridge, Massachusetts 02142 
    
by 
 
Covance Early Clinical Services  
3402 Kinsman Boulevard 
Madison, Wisconsin 53704 
Page 2 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 2 of 48 
 STUDY IDENTIFICATION 
Sponsor CoLucid Pharmaceuticals, Inc. 
 222 Third Street, Suite 1320 
 Cambridge Massachussets 02142 
  (Main Telephone No.) 
  (Main Facsimile No.)  
 
Sponsor’s Study Contact  
  
 CoLucid  Pharmaceuticals, Inc. 
 222 Third Street, Suite 1320 
 Cambridge Massachussets 02142 
  (Office Telephone No.) 
  (Office Facsimile No.)  
 Medical Monitor To be determined  
  Clinical Site  Covance Clinical Research Unit Inc. 
 3402 Kinsman Boulevard 
 Madison, Wisconsin 53704 
  (Main Telephone No.) 
  (Main Facsimile No.) 
 Principal Investigator /  
Authorized User  
 Covance Clinical Research Unit , Inc.  
  (Office Telephone No.) 
  
 Main Clinical Laboratory  Meriter Laboratories  
 36 South Brooks Street 
 Madison, Wisconsin 53715 
  (Main Telephone No.) 
 
Page 3 of 49
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 3 of 48 
 Bioanalytical Laboratory  Covance Laboratories, Inc. 
 3301 Kinsman Boulevard  
 Madison, Wisconsin 53704 
  (Main Telephone No.) 
 
Radioanalytical Laboratory  Covance Laboratories, Inc. 
 3301 Kinsman Boulevard 
 Madison, Wisconsin 53704 
  (Main Telephone No.) 
 Radiation Safety Officer   
 Covance Inc.  
  (Office Telephone No.) 
  
 Clinical Nuclear Pharmacist   
 Covance Inc.  
  (Office Telephone No.) 
  
 Protocol Biostatistician   
 Covance Biometrics  
  (Office Telephone No.) 
  
 Protocol Pharmacokineticist  
 Covance Biometrics  
  (Office Telephone No.) 
  
 Protocol Medical Writer   
 Covance Global Medical and Regulatory Writing 
  (Office Telephone No.) 
  
Page 4 of 49
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 4 of 48 TABLE OF CONTENTS  
TITLE PAGE  .......................................................................................................................1 
STUDY IDENTIFICATION ...............................................................................................2  
TABLE OF CONTENTS  .....................................................................................................4  
ABBREVIATIONS .............................................................................................................8  
1 SYNOPSIS  .............................................................................................................10  
2 INTRODUCTION  .................................................................................................13  
2.1 Background ................................................................................................13  
2.1.1  Nonclinical Background ................................................................13  
2.1.1.1  Nonclinical Metabolism and Excretion  .....14  
2.1.2  Clinical Background  ......................................................................14  
2.1.2.1  Clinical Pharmacokinetics  .........................15  
2.2 Dose Rationale  ...........................................................................................15  
2.3 Study Rationale  ..........................................................................................15  
3 STUDY OBJECTIVES  ..........................................................................................16  
4 INVESTIG ATIONAL PLAN  ................................................................................16  
4.1 Study Design  ..............................................................................................16  
4.2 Discussion of Study Design .......................................................................18  
5 SUBJECT SELECTION  ........................................................................................18  
5.1 Inclusion Criteria  .......................................................................................18  
5.2 Exclusion Crit eria ......................................................................................19  
5.3 Removal of Subjects from Study Participation  ..........................................21  
6 STUDY PROCEDURES  .......................................................................................22  
6.1 Schedu le of Study Procedures ...................................................................22  
6.2 Study Treatment .........................................................................................26  
6.2.1  Drug Supplies and Accountability .................................................26  
6.2.2  Subject Number and Identification ................................................27  
Page 5 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 5 of 48 6.2.3  Dose Preparation and Administration ............................................27  
6.2.4  Blinding..........................................................................................27  
6.3 Study Restrictions  ......................................................................................28  
6.3.1  Diet, Fluid, and Activity Control ...................................................28  
6.3.2  Concomitant Medications ..............................................................28  
6.3.3  Contraception .................................................................................29  
6.4 Pharmacokinetic, [14C] Radioactivity, and Metabolism Procedures .........29  
6.4.1  Pharmacokinetic, [14C] Radioactivity, and Metabolism Blood 
Sample Collection  ..............................................................29  
6.4.2  Pharmacokinetic, [14C] Radioactivity, and Metabolism Urine 
Sample Collection  ..............................................................29  
6.4.3  [14C] Radioactivity and Metabolism Fecal Sample Collection  ......30  
6.4.4  Emesis Sample Collection  .............................................................30  
6.4.5  Collection of Feminine Hygiene Products .....................................30  
6.4.6  Analytical Methodology ................................................................30  
6.5 Safety Procedures .......................................................................................30  
6.5.1  Adverse Events  ..............................................................................31  
6.5.2  Clinical Laboratory Evaluations ....................................................31  
6.5.3  Vital Signs  ......................................................................................32  
6.5.4  Orthostatic Vital Signs  ...................................................................32  
6.5.5  Twelve- lead Electrocardiograms  ...................................................32  
6.5.6  Physical Examinations  ...................................................................32  
6.5.7  Columbia Suicide Severity Rating Scale  .......................................33  
7 DATA ANALYSES AND SAMPLE SIZE  ...........................................................33  
7.1 Sample Size  ................................................................................................33  
7.2 Study Populations ......................................................................................33  
7.3 Pharmacokinetic Analysis  ..........................................................................33  
Page 6 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 6 of 48 7.4 Statistical Analysis of Pharmacokinetic Data  ............................................35  
7.5 Statistical Analyses of Safety Data  ............................................................35  
7.6 Data Handling and Record Keeping ..........................................................36  
7.7 Quality Control and Quality Assurance .....................................................36  
8 ADMINISTRATIVE ASPEC TS ...........................................................................36  
8.1 Change in Protocol .....................................................................................36  
8.2 Site Initiation Visit/Investigator Meeting  ..................................................37  
8.3 Disclosure ..................................................................................................37  
8.4 Monitoring .................................................................................................37  
8.5 Institutio nal Review Board  ........................................................................38  
8.6 Informed Consent.......................................................................................38  
8.7 Records  ......................................................................................................38  
8.8 Reference to Declaration of Helsinki/Basic Principles  ..............................39  
8.9 Financing and Insurance ............................................................................39  
INVESTIGATOR AGREEMENT .....................................................................................40  
SPONSOR AGREEMENT  ................................................................................................41  
REFERENCES  ..................................................................................................................42  
APPENDIX A - CLINICAL LABORATORY EVALUAT IONS  ....................................43  
APPENDIX B - BLOOD SAMPLING SUMMARY  ........................................................44  
APPENDIX C - ADVERSE EVENTS  ..............................................................................45  
1 ADVERSE EVENTS  .............................................................................................45  
1.1 Definition of Adverse Events.....................................................................45  
1.2 Categorization of Adverse Events .............................................................45  
1.3 Pregnancy  ...................................................................................................46  
1.4 Definition  of Serious Adverse Events........................................................47  
1.5 Unexpected Adverse Drug Experience  ......................................................47  
1.6 Reporting....................................................................................................47  
Page 7 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 7 of 48 TABLE OF TABLES  A
ND FIGURES  
Table 6-1  Study Flow Chart ............................................................................................. 23  
Table 6-2  Study Drugs ..................................................................................................... 26  
Figure  4-1 
Study Design Schematic  ................................................................................. 17  
Page 8 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 8 of 48 ABBREVIATIONS  
AUC extrap percentage of AUC that is due to extrapolation from the last 
measurable concentration  
%FR  percentage of lasmiditan recovered in feces  
%UR  percentage of lasmiditan recovered in urine  
5-HT serotonin  
5-HT 1B 5-HT 1B receptor  
5-HT 1F 5-HT 1F receptor  
AE adverse event  
Aef amount excreted in feces over sampling interval  
Aeu amount excreted in urine over sampling interval  
AME  absorption, metabolism, and excretion  
AUC  area under the concentration -time curve  
AUC 0-∞ area under the concentration -time curve extrapolated to 
infinity  
AUC 0-∞ Blood/Plasma 
Ratio  AUC 0-∞ of total radioactivity in blood/AUC 0-∞ of total 
radioactivity in plasma  
AUC 0-∞ Plasma 
Lasmiditan/ Total 
Radioactivity Ratio  AUC 0-∞ of lasmiditan in plasma/AUC 0-∞ of total radioactivity 
in plasma  
AUC 0-t area under th e concentration -time curve from Hour 0 to the 
last measurable concentration  
BMI  body mass index  
CBC  complete blood count  
CFR  Code of Federal Regulations  
CL/F  apparent oral clearance (for lasmiditan only)  
CL R renal clearance  
Cmax maximum observed concentration  
CNS  central nervous system  
CRF  Case Report Form  
C-SSRS  Columbia Suicide Severity Rating Scale  
CV%  coefficient of variation  
CYP  cytochrome  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
Page 9 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
Final 1.0:23 January 2017  Page 9 of 48 FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
HIV human immunodeficiency virus 
IB Investigator Brochure  
ICF Informed Consent Form  
IRB Institutional Review Board  
IV intravenous  
λZ apparent terminal elimination rate constant  
No. number  
PK pharmacokinetic (s) 
QTcF  QT interval corrected for heart rate using Fridericia's formula  
RBC  red blood cell  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
t1/2 apparent terminal elimination half -life 
TFLs  tables, figures, and listings  
tmax time to maximum concentration  
Total %FR  cumulative % FR  
Total %UR  cumulative % UR 
Total A eu cumulative Aeu 
Total A ef cumulative A ef
UA urinalysis  
US United States  
Vz/F apparent volume of distribution  
WBC  white blood cell 
Page 10 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 10 of 48 
 1 SYNOPSIS  
Title of Study:  A Phase 1 Study t o Investigate the Absorption, Metabolism, and Excretion of 
[14C]-Lasmiditan Following Single Oral Dose Administration in Healthy Male and 
Female  Subjects  
Objectives:  Primary:  
• to assess the pharmacokinetics (PK), metabolism, and routes and extent of 
elimination of a single oral dose of 200 mg (approximately 100 µCi) 
[14C]-lasmiditan in healthy male and female subjects . 
Secondary:  
• to characterize and identify metabolites of lasmiditan in plasma, urine, and 
feces; 
• to assess the safety and tolerability of lasmiditan . 
Methodology/Stud y 
Design:  This study will be an open -label, nonrandomized, absorption, metabolism, and 
excretion study of [14C]-lasmiditan administered as a 200 -mg (approximately 
100 µCi) oral solution to 8 healthy male and female subjects , following at least a 
10-hour fast from food (not including water). 
 
 
PK = pharmacokinetic.  
Note: Single oral dose of [14C]-lasmiditan  at 200 mg (approximately 100 µCi)  administered  
orally to subjects in a fasted state. 
Subjects will be confined at the clinical site from the time of Check -in (Day  -1) 
until Discharge (between Days 9 and 14, inclusive ). After completing discharge 
procedures, subjects will be discharged from the clinical site on Day 14 or as early as Day 9, provided radioactivity has reached all of the following threshold values:  
• plasma radioactivity levels below the limit of quantitation; AND  
• ≥90% of the dose is recovered; AND  
• urine total radioactivity ≤1% of the administered dose for 2 consecutive 24-hour intervals; AND  
• fecal total radioactivity  ≤1% of the administered dose for 2 consecutive 
24-hour intervals.  
Pharmacokinetic and radioanalytical samples will be obtained through at least 
192 hours (8 days) postdose and metabolism samples will be obtain ed through 
96 hours (4 days) postdose.  
Number of Subjects:  Eight subjects will be enrolled in order that a minimum of 6 subjects complete  the 
study.  Every effort will be made to enroll 4 females and 4 males in this study.  
Page 11 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 11 of 48 
 Diagnosis and Main 
Criteria for 
Inclusion:  Healthy male and female subjects between  18 and 60 years of age, inclusive, with a 
body mass index  of 18.5 to 32.0 kg/m2, inclusive . 
Females must be nonpregnant, nonlactating, and either postmenopausal (defined as no menstrual period for at leas t 12 months and confirmed by a serum 
follicle -stimulating hormone level of ≥40 mIU/mL ), surgically sterile (e .g., bilateral 
oophorectomy, salpingectomy, and/or hysterectomy) for at least 90 days prior to 
Screening , or must have undergone bilateral tubal ligation and agree to use effective 
contraception. For all females, the pregnancy test results must be negative at 
Screening and Check -in. 
Test Product(s), 
Dose, and Mode of 
Administration:  Subjects  will receive a single dose of 200 mg (approximately 100  µCi) lasmiditan  
as an oral solution after at least a 10-hour fast . 
Duration of 
Treatment:  Planned Enrollment/Screening Duration: up to  28 days 
Length of Confinement: Day -1 through Day  9 or up to Day 14 
Follow -up Phone Call: 4 ± 2 days after Discharge  
Planned Study Conduct Duration (Screening to Follow -up Phone Call ): 13 days 
(minimum) to 49  days (maximum)  
Criteria for 
Evaluation: Safety  Safety endpoints for this study  include : adverse events, clinical l aboratory 
evaluations , vital sign measurements  (including orthostatic vital sign 
measurements) , 12-lead electrocardiograms, physical examination  finding s, and the 
Columbia Suicide Severity Rating Scale . 
Criteria for 
Evaluation: Pharmacokinetics  The follow ing PK parameters will be calculated, whenever possible, based on the 
plasma  concentrations of lasmiditan  and total radioactivity  in plasma and blood: 
maximum observed concentration ( Cmax), time to maximum concentration ( tmax), 
area under the concentration -time curve (AUC) from Hour  0 to the last measurable 
concentration ( AUC 0-t), AUC extrapolated to infinity ( AUC 0-∞), percentage of AUC 
that is due to extrapolation from the last measurable concentration (%AUC extrap), 
apparent terminal elimination rate constant ( λZ), apparent terminal elimination 
half-life ( t1/2), apparent oral clearance (CL/F, for lasmiditan  only), apparent volume 
of distribution (Vz/F, for lasmiditan  only), AUC 0-∞ of total radioactivity in 
blood/AUC 0-∞ of total radioactivity in plasma (AUC 0-∞ Blood/Plasma Ratio ), and 
AUC 0-∞ of lasmiditan  in plasma/AUC 0-∞ of total radioactivity in plasma (AUC 0-∞ 
Plasma Lasmiditan /Total Radioactivity Ratio) . 
The following PK parameters will be calculated, whenever possible, based on the urine concentrations of  lasmiditan  and total radioactivity: amount excreted in urine 
over sampling interval ( A
eu), cumulative A eu (Total A eu), renal clearance (CL R; for 
lasmiditan  only), percentage of lasmiditan recovered in urine ( %UR), and 
cumulative %UR (Total %UR) . 
The following PK parameters will be calculated, whenever possible, based on the fecal concentrations of  total radioactivity: amount excreted in the feces over 
sampling interval ( A
ef), cumulative A ef (Total A ef), percentage of lasmiditan 
recovered in feces (%FR), and cumulative % FR (Total %FR) . 
Other parameters may be added as appropriate. Final PK parameters reported will be detailed in the Statistical Analysis Plan.  
PK parameters for the metabolites
 of lasmiditan  will be calculated, as deemed 
appropriate, based on plasma , urine, and fecal concentration levels.  
Page 12 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 12 of 48 
 Statistical Methods:  Descriptive statistics (mean, standard deviation, coefficient of variation  [CV%],  
geometric mean, geometric CV%, etc. ) will be calculated for the PK parameters. No 
formal statistical analyses are planned.  
Page 13 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 13 of 48 
 2 INTRODUCTION 
2.1 Background 
Migraine  is a common neurological disorder characterized by severe headaches, nausea, 
photophobia, phonophobia, and vomiting. In its 2010 Global Burden of Disease survey, 
the World Health Organizations ranked migraine as one of the 7 most debilitating conditions and as the third most common disease in the world in both males and females. 
Migraine was previously attributed to cycles of vasoconstriction with reactive 
vasodilation that activated the nociceptive terminals on the cerebral and extracerebral vasculature.  It is now believed that this dilation of cerebral and extracerebral blood 
vessels is secondary to noxious sensory signals transmitted through the trigeminal system .
1 
The current first -line treatment for migraine is triptans, selective serotonin (5 -HT) 1B 
receptor (5 -HT 1B) agonists. Agonism at 5- HT 1B results in vasoconstriction and subsequent 
migraine relief.  Because of their vasoconstrictive mechanis m, triptans are contraindicated 
in patients with coronary artery disease. In addition, triptans are associated with a relatively high incidence of neck, jaw, and chest symptoms of unknown etiology that limit tolerability. Concerns about cardiovascular safe ty are believed to limit the 
prescription of triptans to less than 50% of those suffering from migraine.
2 There is a 
large, unmet need to provide m igraine treatment for individuals for whom triptans are not 
an option. 
CoLucid Pharmaceuticals, Inc. (CoLucid) is developing lasmiditan (COL-144), a small 
molecule 5-HT 1F receptor (5 -HT 1F) agonist. Lasmiditan is intended for the acute 
treatment of migra ine patients with and without aura. In preclinical models relevant to 
migraine, selective 5 -HT 1F agonists have been shown to inhibit trigeminal nociceptive 
processing without affecting blood vessel tone. The non-vasoconstrictive mechanism of selective 5 -HT
1F agonists may offer migraine relief to those unable to use triptans. 
2.1.1 Nonclinical Background 
The primary adverse event s (AEs) identified in single - and repeat -dose toxicology studies 
with intravenous ( IV) or oral administration of lasmiditan were central ne rvous system 
(CNS )-related and were accompanied by emesis in dogs and reductions in body weight or 
body weight gain across species. The incidence and severity of CNS -related clinical signs 
Page 14 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 14 of 48 
 was dose dependent and onset tended to coincide with the time to maximum observed 
concentration (t max). These signs were transient and spontaneously resolved within 1 and 
6 hours, respectively, of IV and oral dosing. Aside from the CNS- related clinical signs, 
there was no consistent evidence of a common, specific target organ of toxicity across species.  
The no-observed -adverse -effect level s calculated from a 26-week repeat -dose study in 
rats, a 39-week repeat -dose study in dogs, and a 13-week repeat -dose study in mice were 
2 to 5 times higher than the projected exposures at the 200-mg dose. 
2.1.1.1 Nonclinical Metabolism  and Excretion  
Lasmiditan showed negligible in vitro  metabolism by microsomes and human 
recombinant cytochromes (CYPs), but there was higher turnover in hepatocytes and 
S9 fractions, suggesting that metabolism may depend on other enzymes than CYPs. A 
total of 13 metabolites were detected in incubations with hepatocytes of animal species and 12 with human hepatocytes. No metabolites were unique to humans. 
The excretion of drug-related products from rats and dogs dosed with either oral or IV 
[
14C]-lasmiditan was relatively rapid with the majority excreted within 48  hours of 
dosing. During the first 48  hours, urinary e xcretion was approximately 60% in rat s and 
45% in dogs. 
2.1.2 Clinical Background 
Five Phase 1 studies of las miditan have been completed using IV, sublingual, and oral 
formulations of lasmiditan in 213 healthy subjects, two  Phase 2 studies have been 
completed with lasmiditan in the acute treatment of migraine in 393 patients, and one 
Phase 3 study (COL MIG-301) has been completed with 1239 patients treated with 
lasmiditan . A second Phase 3 study (COL MIG-302) evaluating 50, 100, and 200 mg  
lasmiditan compared to placebo in the acute treatment of migraine is ongoing as is a Phase 3 , open- label,  one-year dosing study to assess long -term safety (COL  MIG -305). 
In healthy male and female subjects, oral doses of lasmiditan up to 400 mg were not associated with drug -related serious AEs (SAEs) or withdrawals due to AEs. The most 
frequently reported AEs in all lasmiditan groups were tiredness, drowsiness, dizziness, and paresthesia. At the highest dose of 400 mg lasmiditan, most AEs were mild in intensity and none were severe.  
Page 15 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 15 of 48 
 2.1.2.1 Clinical Pharmacokinetics  
The pharmacokinetics (PK) of lasmiditan were linear with respect to maximum observed 
concentration (C max) and area under the concentration -time curve (AUC) following 
administration of 25 to 400 mg lasmiditan as an oral solution.  The tmax was approximately 
1.9 hours and t he mean terminal elimination half -life (t 1/2) ranged from 4.66 to 
6.38 hours.  
In subjects receiving oral lasmiditan, 3 major metabolites (M7, M8, and [S, R]-M18) 
were detected. These 3 metabolites were pharmacologically inactive against over 40 
G protein-coupled receptors, ion channels, and transporters. The non-reduced metabolites 
exhibited a t 1/2 of ~4.5 hours, while the reduced metabolites had a t 1/2 greater than 
12 hours. 
2.2 Dose Rationale 
A dose of 200 mg was chosen for this study. The 200-mg dose level, currently under 
investigation as a therapeutic dose in  Phase 3 clinical trials, is safe and well tolerated. 
The radioactive dose will be approximately 100 µCi in 200 mg of [14C]-lasmiditan (i.e., 
0.5 µCi/mg).  
Based on data in male and female Lister Hooded rats (with supporting data from male Sprague Dawley rats), the overall whole body radiation dose following administration of a single 100 µCi dose of [
14C]-lasmiditan is calculated to be 65.9 and 77.0 mrem in 
human male and female subjects, respectively.3 These values for whole body exposure 
are well below the FDA exposure limit of 3000 mrem after a single dose for human isotope studies. Based on these results, a single 100-µCi oral dose of [
14C]-lasmiditan is 
not expected to represent a significant radiation exposure risk to human male or female subjects.  
2.3 Study Rationale 
The purpose of this study is to determine the absorption and excretion kinetics of lasmiditan , and to determine and character ize metabolites present in plasma , urin e, and 
feces  in healthy male and female subjects following a single d ose of 200 mg  
(approximately 100 µCi)  of [
14C]-lasmiditan  administered as an oral solution . 
The optimization of absorption, metabolism, and excretion (AME) parameters is a key  
part of the drug development process. The characteristics of AME modulate the efficacy  
Page 16 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 16 of 48 
 and toxicity of a drug and inform the researcher of the potential impacts of hepatic or 
renal impairment on drug disposition. It is therefore crucial to understand the clearance mechanism and characteristics of metabolism of a new drug.  
It has been established that migranes are more common in the female population, with onset typically occurring during peak child- bearing years. Because lasmidit an will be 
administered to more females than males, females will be included in this AME study. The inclusion of females in this study will ellucidate any relevant differences in lasmiditan AME between male and females.  
3 STUDY OBJECTIVES  
The primary objecti ves of this study are:  
• to assess the PK, metabolism, and routes and extent of elimination of a 
single oral dose of 200 mg (approximately 100 µCi) [
14C]-lasmiditan in 
healthy male and female subjects.  
The secondary objectives of this study are:  
• to character ize and identify metabolites of lasmiditan  in plasma , urine, and 
feces ; 
• to assess the safety and tolerability of lasmiditan . 
4 INVESTIGATIONAL PLAN  
4.1 Study Design  
This s tudy will be an open-label, nonrandomized, AME  study of [14C]-lasmiditan  
administered as a 200-mg (approximately 100 µCi ) oral solution to 8 healthy male and 
female subjects following a t least a  10-hour fast  from food (not including water). 
A schematic of the study design is presented in Figure 4-1. The start of the study is 
defined as the date the first subject enrolled in the study signs an Informed Consent Form 
(ICF). A subject who completes all PK, radioactivity, and metabolism sampling p rior to 
Discharge is considered to have completed the study. The end of the study is defined as the date the last subject completes the Follow-up Phone Call. The planned duration of 
study conduct is up to approximately  49 days from Screening through the Follow-up 
Phone Call. 
Page 17 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 17 of 48 
 Figure  4-1 Study Design Schematic  
 
PK = pharmacokinetic.  
Note: Single oral dose of [14C]-lasmiditan  at 200 mg (approximately 100 µCi) administered  orally to subjects in a 
fasted state.  
Subjects will be confined at the clinical site from the time of Check -in (Day  -1) until 
Discharge ( between Day s 9 and 14, inclusive ). After completing discharge procedures, 
subjects will be discharged from the clinical site on Day 14 or as early as Day  9, provided 
radioactivity has reached all of the following threshold values: 
• plasma  radioactivity levels below the limit of quantitation; AND 
• ≥90% of the dose is recovered; AND  
• urine total radioactivity ≤1% of the administered dose for 
2 consecutive 24-hour intervals; AND  
• fecal total radioactivity  ≤1% of the administered dose for 
2 consecutive 24-hour intervals. 
Sample collection and confinement will continue until discharge criteria are met or the 
maximum stay  (Day  14) is reached, unless otherwise agreed up on by the Sponsor and 
Investigator. A Follow -up Phone Call will be conducted 4 ± 2 days after Discharge. 
Subjects experiencing emesis during the first 4 hours postdose may  be discharged on the 
same day from the clinical site , provided there are no safety c oncerns, and after follow -up 
study procedures are performed. Subjects who are discharged from the study early will not be replaced. 
Safety will be monitored with AE inquiries, clinical laboratory evaluations ( Appendix A ), 
vital sign measurements  (including orthostatic vital sign measurements) , 12-lead 
electrocardiograms (ECGs), physical examination findings , and the Columbia Suicide 
Severity Rating Scale (C -SSRS)  during the study.  
Page 18 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 18 of 48 
 Pharmacokinetic and radioanalytical  sample s will be obtained through at least 192 hours 
(8 days) postdose and  metabolism samples will be obtained through 96 hours (4  days) 
postdose. A study  flow chart is presented in Table  6-1. 
4.2 Discussion of Study Design  
This study is designed to characterize the AME  of lasmiditan  using radiolabeled drug in 
healthy adult male  and female subjects to support its further development and 
registration.  
The study will be conducted as an open- label trial because the study measures are 
objective outcomes (e.g., total radioactivity in select biological matrices, metabolite 
profiling/characterization). Conducting the trial in healthy subjects will allow the evaluation of lasmiditan  metabolism in the absence of concomitant medications. The 
dose, subject population, study duration, and sample collection timing are considered adequate to achieve the study objectives.  
5 SUBJECT SELECTION  
Subjects who meet all the in clusion criteria and for whom  none of the exclusion criteria 
apply will be eligible to be enrolled into the study.  Safety evaluations may be repeated at 
the Investigator’s (or designee’s) discretion. 
Eight  subjects will be enrolled to have at least 6 subje cts complete the study.  Every effort 
will be made to enroll 4  females and 4 males in this study.  
5.1 Inclusion Criteria  
Subjects who meet the following criteria may  be included in the study: 
1. males and females , between 18 and 60 years of age , inclusive, at 
Screening ; 
2. have a body mass index range of 18.5 to 32.0 kg/m
2, inclusive , at 
Screening ; 
3. in good health, determined by no clinically significant findings from 
medical history, 12-lead ECG, and vital signs measurement s at Screening 
or Check -in (Day  -1) as determined by the Investigator (or designee) ; 
4. clinical laboratory evaluations (including clinical c hemistry panel  [fasted 
at least 10 hours], hematology/complete blood count [ CBC ], and 
urinalysis [ UA]; Appendix A ) within the reference range for the test 
Page 19 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 19 of 48 
 laboratory at Screening and Check -in, unless deemed not clinically 
significant by the Investigator  (or designee) ; 
5. negative test for selected drugs of abuse at Screening ( does not include 
alcohol) and at Check-in (does include alcohol ; Appendix A ); 
6. negative hepatitis panel (including hepatitis B surface antigen  and 
hepatitis C virus antibody and negative human immunodeficiency virus 
(HIV) antibody screens ( Appendix A ) at Screening ; 
7. females must be nonpregnant, nonlactating, and either postmenopausal 
(defined as no menstrual period for at least 12 months and confirmed by a serum follicle -stimulating hormone [FSH] level of ≥40 mIU/mL ), 
surgically sterile  (e.g., bilateral  oophorectomy, salpingectomy, and/or 
hysterectomy) for at least 90  days  prior to Screening, or must have 
undergone bilateral tubal ligation and agree to use effective contraception as detailed in Section 6.3.3. For all females, the pregnancy test results 
must be negative at Screening and Check- in; 
8. males will be surgically sterile for at least 90 days  prior to Screening or 
when sexually -active with female partners of child -bearing potential will 
agree to use contraception as detailed in Section  6.3.3 from Check -in until 
90 days following Discharge. Male subje cts must also be willing to refrain 
from donating sperm from Check-in until 90 days following Discharge; 
9. able to comprehend and willing to sign an ICF; 
10. a minimum of 1 to 2 bowel movements per day. 
5.2 Exclusion Criteria  
The following will exclude potential subjects from the study:  
1. significant history or clinical manifestation of any metabolic, allergic, infectious, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator  [or designee] ) prior to Check- in; 
2. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) prior to Check- in; 
3. history of stomach o r intestinal surgery or resection that could alter 
absorption or excretion of orally administered drugs prior to Check- in, 
except that cholecystectomy, appendectomy, and hernia repair  will be 
allowed  if it was not associated with complications ; 
Page 20 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 20 of 48 
 4. history or presence of an abnormal ECG  that, in the Investigator’s (or 
designee’s) opinion, is clinically significant at Screening or  Check -in; 
5. history of orthostatic hypotension with or without syncope; 
6. a sustained seated systolic blood pressure >150 mmHg or <90 mmH g or a 
diastolic blood pressure >90 mmHg or <50  mmHg at Screening or 
Check -in. Blood pressure may be retested twice at intervals of 5  minutes. 
The out-of-range blood pressure values will be considered sustained if 
either the systolic or diastolic blood pre ssures are outside the stated limits 
after these 3  assessments;  
7. history of alcoholism or drug addiction within 1 year prior to Check- in; 
8. use of any tobacco - or nicotine-containing products (including but not 
limited to cigarettes, e -cigarettes, pipes, cigars, chewing tobacco, nicotine 
patches, nicotine lozenges, or nicotine gum) within 6 months prior to Check -in, or positive cotinine screen at Screening or Check -in;  
9. participation in more than 1 other radiolabeled investigational study drug trial within  12 months prior to Check-in. The previous radiolabeled study 
drug must have been received more than 6 months prior to Check- in for 
this study and the total exposure from this study and the previous study will be within the recommended levels considered sa fe, per United States 
(US) Title 21 Code of Federal Regulations ( CFR ) 361.1 (e.g., less than 
5,000 mrem whole body annual exposure); 
10. exposure to significant radiation (e.g., serial x -ray or computed 
tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to Check-in; 
11. participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half -lives  (if known) or 
30 days prior to Check -in, whichever is longer; 
12. use of any prescription medications/products within 14 days prior to Check -in, unless deemed acceptable by the Investigator  (or designee) ; 
13. use of any over-the-counter, nonprescription preparations (including vitamins, minerals, an d phytotherapeutic/herbal/plant-derived 
preparations) within 7 days prior to Check- in, unless deemed acceptable 
by the Investigator (or designee); 
14. poor peripheral venous access prior to Check- in; 
Page 21 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 21 of 48 
 15. donation of whole blood from 56 days prior to Screening through 
Discharge, inclusive, or of plasma from 30 days prior to Screening through Discharge, inclusive; 
16. receipt of blood products within 2 months prior to Check- in; 
17. subject is at imminent risk of suicide (positive response to question 4 or 5 on the baseline C-SSRS) or had a suicide attempt within 6 months prior to 
the Screening visit ; 
18. any acute or chronic condition that, in the opinion of the Investigator (or designee) , would limit the subject’s ability to complete or participate in 
this clinical study ; 
19. any other unspecified reason that, in the opinion of the Investigator (or 
designee) or Sponsor, makes the subject unsuitable for enrollment. 
5.3 Removal of Subjects from Study Participation 
Subjects will be informed that they are free to withdraw from the study at any time and for any reason. The Investigator (or designee) may remove a subject from the study if, in 
the Investigator’ s (or designee’s) opinion, it is not in the best interest of the subject to 
continue the study. Subjects may be withdrawn  due to the following: change in 
compliance with inclusion/exclusion criterion that is clinically relevant and affects subject safety, occurrence of AEs, intake of nonpermitted concomitant medication that might affect subject safety or study assessments/objectives, etc.  Notification of 
withdrawal  will immediately be made to the Sponsor’s Study Monitor. In case of 
withdrawal  of study participation, efforts will be made to perform all final study day 
assessments ( Table 6-1). The date the subject is withdrawn from the study and the reason 
for withdrawal  will be recorded on the subject’s Case Report Form ( CRF ). All withdrawn 
subjects  will be followed until resolution of all their AEs or until the unresolved AEs are 
judged by the Investigator (or designee) to have stabilized.  
The entire study may be discontinued at the discretion of the Investigator (or designee) , 
Sponsor, or Sponsor’s Medical Monitor based on the occurrence of the following: 
• AEs unknown to date with respect to their nature, severity, and/or 
duration; 
• increased frequency and/or severity and/or duration of known AEs; 
• medical or ethical reasons affecting the continued performance of 
the study; 
• difficulties in the recruit ment of subjects; 
Page 22 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0:23 January 2017  Page 22 of 48 
 • cancellation of drug development. 
6 STUDY PROCEDURES  
6.1 Schedule of Study Procedures  
A study flow chart is presented in Table 6-1. The total blood volume that will be taken 
during the study is outlined in Appendix B . 
Page 23 of 49
CoLucid 
Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 
8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 23 of 48 
 Table  6-1  Study Flow Chart  
 Screening  Check
-in         
Discharge  Follow -up 
Phone Call  
Study Procedures  Days ( -29 
through -2) Day -1 Day 1  Day 2 Day 3 Day 4 Day 5 Day 6  Day 7  Day 8  (Day 9 or up 
to Day 14)a 4 ± 2  days 
after 
Discharge  
Informed Consent  X            
Demographics  X            
Medical History  X Xb           
Height, Weight, and 
BMI  X Xc           
Hepatitis and HIV 
Screen  X            
Alcohol and Drug 
Screend X X           
Pregnancy Teste X X           
FSHf X            
Confined to the 
Clinical Site   X X X X X X X X X X  
Physical 
Examination   X         Xg   
C-SSRSh X X  X       X  
Vital Signsi X X X X X X X X X X X  
Orthostatic Vital 
Signsj X X X          
12-lead ECGk X X         X  
Page 24 of 49
CoLucid 
Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 
8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 24 of 48 
  Screening  Check
-in         
Discharge  Follow -up 
Phone Call  
Study Procedures  Days ( -29 
through -2) Day -1 Day 1  Day 2 Day 3 Day 4 Day 5 Day 6  Day 7  Day 8  (Day 9 or up 
to Day 14)a 4 ± 2  days 
after 
Discharge  
Clinical Chemistry 
Panel, Complete Blood Count, Urinalysis  X X  X       X  
SAE  Monitoringl X X X X X X X X X X X X 
AE Monitoringm   X X X X X X X X X X 
Prior/Concomitant 
Medication 
Monitoring  X X X X X X X X X X X X 
[14C]-Lasmiditan 
Administrationn   X          
Pharmacokinetic/ 
Radioactivity Blood 
Sampleso   X X X X X X X X X  
Metabolism Blood 
Samplesp   X X  X X      
Urine Samplesq   X X X X X X X X X  
Fecal Samples r   X X X X X X X X X  
AE = adverse event; BMI = body mass index; C -SSRS = Columbia Suicide Severity Rat ing Scale;  ECG = electrocardiogram;  FSH = follicle -stimulating hormone; 
HIV = human  immunodeficiency  virus ; SAE = serious adverse event  
a Early termination procedures to be performed in close proximity to discontinuation of subject from the study. Other procedure s may be performed at Investigator (or designee) or 
Sponsor discretion.  
b Interim medical history only.  
c Weight  only.  
Page 25 of 49
CoLucid 
Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 
8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 25 of 48 
 d Drug screen does not include alcohol testing at Screening but does include an alcohol breath test at Check -in (Day  -1). 
e Females only. A serum pregnancy test will be collected at Screening and Check -in. 
f To confirm postmenopausal status in females only.  
g Abbreviated physical examination only.  
h A baseline version  of the C-SSRS survey will be given  at Screening and the “since last visit” version of the C -SSRS  will be given at Check -in, on Day  2, and at Discharge.   
i Vital sign measurements (oral temperature, respiratory rate, and seated blood pressure  and pulse)  will be obtained at single timepoints at Screening, Check -in, and at 1, 2, 4, 24, 
48, 72, 96, 120, 168, and 192 hours postdose. If the subject is not discharged on Day  9, additional vital sign meas urements will be performed every 24 hours until Discharge. Vital 
sign measurements will be performed with the subject in a seated position after the subject has rested for at least 5  minutes. When the timepoints for blood draws and vital sign 
measurements coincide, the vital sign measurements will be collected prior to the blood draws and as close to the scheduled timepoint as possible.  
j Orthostatic blood pressure and pulse will be obtained at Screening, Check -in, at 0  Hour (predose), and at 1.25, 1.75, and 2.25 hours postdose. Blood pressure and pulse will first 
be collected with the subject in a seated position after the subject has rested for at least 5 minutes. Blood pressure and pulse will be taken again after the subject has been standing 
for 2 to 4 minutes. The same arm will be used during each assessment of blood pressure and pulse.  When the timepoints for blood draws and orthostati c vital sign measurements 
coincide, the orthostatic vital sign measurements will be collected prior to the blood draws and as close to the scheduled timepoint as possible.  
k Single 12 -lead ECGs  obtained at Screening, Check -in, and Discharge . The 12-lead ECGs will be collected after the subject has been resting in a supine position for at least 
10 minutes. When the timepoints for blood draws and ECGs  coincide, the ECGs  will be collected prior to the blood draws and as close to the scheduled timepoint as poss ible. 
l Any SAEs occurring after the subject signs the Informed Consent Form will be recorded . 
m Subjects will be monitored for AEs beginning at initiation of study drug. An AE inquiry will be performed at each postdose vi tal sign measurement.  
n Single ora l dose of [14C]-lasmiditan  at 200 mg (approximately 100 µCi)  administered orally to subjects in a fasted state . 
o Blood samples for pharmacokinetics and radioanalysis will be collected at 0 Hour (predose) and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, and 192 hours postdose. 
If the subject is not discharged on Day  9, additional blood samples will be collected every 24 hours until Discharge . If the plasma radioactivity le vels fall below the limit of 
quantitation , then samples for radioanalysis will no longer be collected.  
p Blood samples for metabolite profiling and identification collected at 0 Hour (predose) and at 2, 4, 8, 24, 72, and 96 hours postdose . 
q Urine samples collected at -12 to 0 hours (predose, the last void within 1 hour prior to dosing) and at the following collection intervals: 0 to 6, 6 to 12, 12 to 24,  24 to 48, 48 to 
72, 72 to 96, 96 to 120, 120 to 144, 144 to 168, and  168 to 192 hours postdose. If the subject is not discharged on Day  9 (after the 192  hour postdose timepoint) , then urine will be 
collected at 24 -hour intervals until Discharge.  
r If possible, a baseline fecal sample will be collected predose (within 24 hours of dosing). Fecal samples will also be collected daily (24 -hour intervals) from Days 1 through 9. If a 
subject is not discharged on Day  9, then fecal samples will be collected at 24 -hour intervals until Discharge .
Page 26 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 26 of 48 
 6.2 Study Treatment  
6.2.1 Drug Supplies and Accountability  
The Sponsor (or designee) will provide the Investigator  (or designee) with adequate 
quantities of the study drugs ( Table 6-2 ). 
Table  6-2  Study Drug s 
Study Drug  [14C]-Lasmiditan  Lasmiditan  
Forma Powder  Powder  
Specific Activity  0.5µCi/mg Not applicable  
Supplier  ARCINOVA  Ltd. Aptuit (UK) Ltd.  OR Produits 
Chimiques Auxillaires et de Synthèse 
(PCAS)  
Manufacturer  ARCINOVA  Ltd. Aptuit (UK) Ltd.  OR Produits 
Chimiques Auxillaires et de Synthèse 
(PCAS)  
aSpecific ingredients/purity will be identified in the Certificate of Analysis (or equivalent) that is supplied with the 
study drug(s).  
The lot numbers for the study drug (s) will be provided to the clinical site by the 
supplier/manufacturer as soon as available.  
Nonradiolabeled s tudy drugs will be stored at room temperature (between 15 °C and 
30°C) under secure conditions and protected from light). Radiolabeled study drug will be 
stored in a freezer set to maintain -80°C (±10 °C). 
The Investigator (or designee) will maintain an accurate record of the receipt of the 
clinical trial materials as shipped by the Sponsor (or designee), including the date 
received. One copy of this receipt will be returned to the Sponsor when the contents of the shipment have been verified. In addition, an accurate drug disposition record will be kept, specifying the amount dispensed to each subject and the date of dispensation. This drug accountability  record will be available for inspection at any time. At the completion 
of the study, the original drug accountability  record will be available for review by the 
Sponsor on request. 
At the completion of the study, all unused drug supplies will be returned to the Sponsor 
(or designee) or disposed of by the clinical  site, per the Sponsor’s (or designee’s) written 
instructions. 
Page 27 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 27 of 48 
 6.2.2 Subject Number and Identification  
Subjects will be assigned a number by clinical site staff. Assignment of numbers will be 
in ascending order and no numbers will be omitted. Subject numbers will be used on all 
study documentation. For subjects who are withdrawn  by the Investigator  (or designee)  
or who voluntarily withdraw prematurely from the study, replacement subjects will not be enrolled. 
6.2.3 Dose Preparation and Administration  
Each unit dose will be prepared by qualified clinical staff.  Each unit dose container will 
be appropriately labeled.  
Appropriate unit doses will be administered to consecutively-numbered subjects. Although the timing of events requires that each subject will be consistently administered the appropriate dose at specific times, the exact dose time of consecutive subjects may be staggered to obviate the need to have all subjects on precisely the same study schedule. For each dose, the subject’s actual dose time will be recorded in the source documents 
and transcribed into the CRFs.  
Each dose will be administered orally with room temperature water  to attain a total 
volume of 240 mL (dose volume + bottle rinses + room temperature water) . A hand and 
mouth check will be performed to verify that the dose administered was swallowed. Doses will be preceded by an overnight fast ( i.e., at least 10 hours) from food (not 
including water) and will be followed by a fast from food (not including water) for at least 4 hours postdose. Except as part of dose administration, subjects will restrict their consumption of water for 1 hour predose and for 2 hours postdose; at all other times during the study, subjects may consume water ad libitum.  
Except when they are using the toilet, study subjects will be observed for approximately 
4 hours postdose to monitor potential AEs and/or nausea. Subjects will not lay supine for 
1 hour following each dose administered, except as necessitated by the occurrence of an AE(s) and/or study procedures. 
6.2.4 Blinding  
This is an open- label study.  
Page 28 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 28 of 48 
 6.3 Study Restrictions  
6.3.1 Diet, Fluid, and Activity Control 
Subjects are required to  refrain from use of tobacco- or nicotine- containing products 
within 6  months prior to Check -in until Discharge . 
Subjects are required to  abstain from consuming alcohol- , grapefruit -, or 
caffeine-containing foods and beverages for 72 hours prior to Check -in until Discharge, 
unless deemed acceptable by the Investigator  (or designee) . 
Subjects will refrain from strenuous exercise from 48  hours prior to Check-in until 
Discharge and will otherwise maintain their normal level of physical activity throughout 
the entire study ( i.e., will not begin a new exercise program nor participate in any 
unusually strenuous physical exertion). 
While confined at the clinical site, subjects will receive a sta ndardized high fiber diet at 
scheduled times that do not conflict with other study- related activities.  Prune juice may 
be administered on an as-needed basis to aid in normal bowel function and will not be 
considered a concomitant medication . 
6.3.2 Concomitant Medications  
Subjects will refrain from participation in any other investigational study drug trial in 
which  receipt of any investigational drug occurred within 5 half- lives (if known) or 
30 days , whichever is longer, prior to C heck -in until Discharge. 
Subjects will also refrain from the use of any prescription medications /products during 
the interval from 14 days prior to Check-in through Discharge, unless deemed acceptable 
by the Investigator (or designee). In addition, subjects will refrain from the use of any over-the-counter nonprescription medications  (including vitamins, minerals, and 
phytotherapeutic/herbal/plant-derived preparations) from 7 days prior to Check-in 
through Discharge, unless deemed acceptable by the Investigator  (or designee) . 
A mild laxative ( i.e., Milk of Magnesia
®, Colace®) may be used to help with bowel 
movements if necessary.  Up to  2 grams per day of acetaminophen may be administered if 
approved by the Investigator ( or designee). Subjects on hormone replacement therapy 
will b e allowed to continue their regimen throughout the study. The administration of any 
other concomitant medications during the study is prohibited without prior approval of 
Page 29 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 29 of 48 
 the Investigator  (or designee), unless its use is deemed necessary in a medical emerg ency. 
Any medication taken by a subject during the study and the reason for its use will be 
documented in the source documents and the CRF.  
6.3.3 Contraception  
Males will be surgically sterile for at least 90 days  prior to Screening or must use a male 
condom wi th spermicide from Check -in (Day  -1) until 90 days following Discharge when 
sexually -active with female partners of child -bearing potential.  
Males will refrain from sperm donation from Check-in until 90 days following Discharge.  
Females will be surgically sterile  (e.g., bilateral oophorectomy, salpingectomy, and/or 
hysterectomy ) for at least 90  days  prior to Screening, postmenopausal, or will have 
undergone bilateral tubal ligation AND will agree to use 1 of the following methods of contraception from Check -in until 90 days following Discharge: 
• diaphragm with spermicide ; 
• cervical cap with spermicide ; 
• use by the male partner of a condom with spermicide. 
6.4 Pharmacokinetic , [
14C] Radioactivity, and Metabolism Procedures  
6.4.1 Pharmacokinetic , [14C] Radioactivity, and Metabolism  Blood Sample 
Collection  
Blood samples for PK analysis , total radioactivity, and metabolite profiling and 
identification  will be collected via direct venipuncture. Blood samples will be collected at 
the timepoints specified in Table 6-1. The number of blood samples and total blood 
volume required for analysis of PK, radioactivity, and/or for metabolite characterization are presented in  Appendix B . 
6.4.2 Pharmacokinetic, [
14C] Radioactivity, and Metabolism Urine Sample 
Collection  
Urine samples for PK analysis , total radioactivity, and metabolite profiling  and 
identification will be collected  during the time intervals  specified  in Table 6-1. 
Page 30 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 30 of 48 
 6.4.3 [14C] Radioactivity and Metabolism Fecal Sample Collection  
Fecal samples for total radioactivity and metabolite profiling and identification will be 
collected  during the time intervals specified  in Table 6-1. 
6.4.4 Emesis Sample Collection  
For subjects experiencing emesis within 4 hours following dosing, vomitus will be 
collected . Attempts will be made to collect vomitus from subjects experiencing emesis 
after 4 hours postdose. All vomitus collected will be  stored for possible analysis. The 
time and date  of collection will be recorded on the subject’s source documents and CRF. 
Vomitus will be analyzed as deemed appropriate. 
6.4.5 Collection of Feminine Hygiene Products  
For female subjects experiencing menses, all f eminine hygiene products ( e.g., tampons, 
pads, etc. ) will be collected from dosing until Discharge and will be stored for possib le 
future analysis , as determined by the Sponsor. The time and date of collection will be 
recorded on the subject’s source documents and CRF. Feminine hygiene products will be 
analyzed for radioactivity only as deemed appropriate by the Sponsor (based on the 
overall recovery data) . 
6.4.6 Analytical Methodology 
Plasma  and urine concentrations of  lasmiditan  will be determined by Covance 
Laboratories, Inc. using a validated analytical procedure. Total radioactivity 
concentrations will be determined  by Covance Laboratories, Inc.  in whole blood, plasma, 
urine, and feces using liquid scintillation counting. Profiling and characterization of metabolites in plasma, urine, and feces will be c onducted by Covance Laboratories, Inc. 
using standard laboratory procedures. Specifics of the analytical methods will be provided in a separate document.  
6.5 Safety Procedures  
Safety  evaluations may be repeated  at the  Investigator ’s (or designee ’s) discretion . 
Every effort will be made to schedule and perform the procedures in accordance with the 
nominal time, giving considerations to appropriate posture conditions, practical restrictions, and the other procedures to be performed at the same timepoint. The order of priority for scheduling procedures around a timepoint is (in descending order of priority): 
Page 31 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 31 of 48 
 • dosing 
• blood sampling for PK, radioanalysis, and metabolite identification  
• start and end of urine and feces collections (for drug assay)  
• vital sign measurements  
• ECGs  
• blood and urine samples for clinical laboratories 
• physical examinations  
• C-SSRS  
6.5.1 Adverse Events  
Adverse event definitions (assignment of severity, causality, action taken, and outcome) 
and procedures for reporting serious AE s are detailed in Appendix C . 
Subjects will be asked a nonleading question such as “Have there been any changes in your health status since Screening/since you were last asked?” at the timepoints specified  
in Table 6-1 to assess for the occurrence of AEs . Subjects will also be encouraged to 
voluntarily report AEs occurring at any other time during the study. 
All nonserious AEs, whether volunteered, reported during AE inquiries, or noted on 
physical examination, will be recorded from initiation of study drug  until study 
completion. Nonserious AE information should also be collected from the start of a 
washout period or other observational period intended to establish a baseline status for the subjects.  Serious AEs will be recorded from the time the subject signs the ICF until 
study completion. 
All AEs (nonserious and serious) should be followed until the event has resolved, 
returned to baseline, or is assessed as stable by the Investigator (or designee).  
6.5.2 Clinical Laboratory Evaluations 
Clinical laboratory evaluations (including clinical c hemistry panel  [fasted at least 
10 hours], CBC, and UA ; Appendix A ) will be collected at the timepoints specified  in 
Table 6-1. 
Screens for a hepatitis panel and HIV antibody will be performed at Screening.  A drug 
screen for selected drugs of abuse (not including alcohol) will be performed at Screening 
and repeated (including alcohol) at Check -in.  
Page 32 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 32 of 48 
 6.5.3 Vital Signs  
Vital sign  measurement s (including oral temperature, respiratory rate, and seated  blood 
pressure an d pulse) will be obtained at the timepoints specified in  Table 6-1. Seated 
blood pressure and pulse will be measured after the subject has been seated  for at least 
5 minutes.  
6.5.4 Orthostatic Vital Signs  
Orthostatic vital sign measurements ( seated  and standing blood pressure and pulse) will 
be obtained at the timepoints specified in Table 6-1. The seated  blood pressure and pulse 
will be measured after the subject has been seated  for at least 5 minutes. The subject will 
then stand for at least 2 minutes, but no more than 4 minutes, and the standing blood 
pressure and pulse will be measured.  
Postural hypotension will be defined as a drop in blood pressure of >10 mmHg for diastolic blood pressure , >20 mmHg for systolic blood pressure, or an increase of 
>30 beats per minute in heart rate.  
6.5.5 Twelve-l ead Electrocar diograms 
A 12 -lead ECG will be obtained at the timepoints specified in Table 6-1. Subjects will be 
supine for at least 10 minutes prior to obtaining an ECG measurement.  
Electrocardiogram parameters (including heart rate; PR, QRS, and QT intervals; and Q T 
interval corrected for heart rate using Fridericia’s formula  [QTcF] ) and the Investigator’s 
overall interpretation of the ECG will be recorded in the CRF.  
6.5.6 Physical Examinations 
A routine physical examination will be performed at the timepoints specified  in 
Table 6-1. An abbreviated exam (including exam of general appearance, skin, thorax/lungs, cardiovascular system , and abdomen) will be performed at the timepoints 
specified in Table 6-1.  
The time and date of the physical examination will be recorded in the CRF and any clinically significant findings will be recorded as AEs.  
Page 33 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 33 of 48 
 6.5.7 Columbia Suicide Severity Rating Scale  
The C -SSRS rates an individual’s degree of suicidal ideation on a scale ranging from 
“wish to be dead” to “active suicidal ideation with specific plan and intent”. The scale 
intends to prospectively identify and classify suicidal ideation and behavior based on a semi -structured interview by the Investigator or designee trained in administering the 
questionnaire. Two versions of the C- SSRS will be used: 
• the baseline version wi ll be administered at Screening ; 
• the “since last visit” version will be administered on Days -1, 2, and at Discharge. 
If present, suici dal ideation will be classified in 5 classes (1 -5), the intensity of suicidal 
ideation will be classified in 5 dimensions, and any suicidal behavior will be classified in 6 classes (actual attempt, interrupted attempt, aborted attempt, preparatory acts tow ards 
an attempt, suicidal behavior, suicide). 
7 DATA ANALYSES  AND SAMPLE SIZE  
7.1 Sample Size  
The sample size chosen for this study was based on precedent set by other PK studies of 
similar nature and was not based on power calculations. 
7.2 Study Populations  
The PK  population will consist of all subjects who received at least 1 dose of study drug 
and have evaluable PK data.  
The safety population will consist of all subjects who received at least 1 dose of study 
drug and have at least 1 postdose safety assessment.  
7.3 Pharmacokinetic Analysis 
For each subject, the following PK parameters will be calculated, whenever possible, based on the plasma  concentrations of lasmiditan  and total radioactivity  in plasma and 
blood, according to the model independent approach
4: 
Cmax maximum observed concentration 
tmax time to maximum concentration  
AUC 0-t area under the concentration -time curve (AUC) from 
Hour 0 to the last measurable concentration, calculated 
Page 34 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 34 of 48 
 using the linear trapezoidal rule for increasing 
concentrations and the logarithmic rule for decreasing concentrations 
AUC
0-∞ AUC  extrapolated to infinity, calculated using the formula: 
  
AUC 0-∞ = AUC 0-t + 
zt
λC 
  
where C t is the last measurable concentration and λZ is the 
apparent terminal elimination rate constant  
%AUC extrap percentage of AUC that is due to extrapolation from the last 
measurable concentration to infinity. 
λZ apparent terminal elimination rate constant, where λZ is the 
magnitud e of the slope of the linear regression of the log 
concentration versus time profile during the terminal phase 
t1/2 apparent terminal elimination half -life (whenever possible), 
where t 1/2 = natural log (2)/ λZ 
CL/F  apparent oral clearance (for lasmiditan  only) 
Vz/F  apparent volume of distribution (for lasmiditan  only) 
AUC 0-∞ Blood/Plasma Ratio  
 AUC 0-∞ of total radioactivity in blood/AUC 0-∞ of total 
radioactivity in plasma  
AUC 0-∞ Plasma lasmiditan/Total Radioactivity Ratio  
 AUC 0-∞ of lasmiditan in plasma/A UC 0-∞ of total 
radioactivity in plasma  
In addition, the following PK parameters will be calculated, whenever possible, for e ach 
subject based on the urine concentrations of lasmiditan  and total radioactivity : 
Aeu amount excreted  in urine over sampling interval 
Total A eu Cumulative Aeu 
CL R renal clearance, where CL R = Aeu/AUC 0-x (where x is the 
last interval collected; for lasmiditan  only) 
%UR  percent age of lasmiditan recovered in urine, where 
%UR  = 100 (A eu/dose) 
Total %UR  Cumulative %UR  
Page 35 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 35 of 48 
 The following PK parameter s will be calculated, whenever possible, for each subject 
based on the fecal concentration of total radioactivity:  
 Aef a mount excreted in the feces over sampling interval  
Total A ef Cumulative Aef 
 % FR percent age of lasmiditan recovered in feces,  where 
%FR = 100 (A ef/dose) 
Total %FR  Cumulative % FR 
Pharmacokinetic calculations will be performed, if appropriate, using commercial 
software such as Phoenix™ WinNonlin® Version 6.4 or higher ( Certara USA Inc. ). 
Pharmacokinetic parameters for the metabolites of lasmiditan  may  be calculated, as 
deemed appropriate, based on plasma , urine, and fecal concentration levels.  
Other parameters may be added as appropriate. Final PK parameters reported will be detailed in the Statistical Analysis Plan ( SAP). 
Pharmacokinetic analysis  will use actual times as recorded on the CRF. Other data 
handling procedures will be detailed in the SAP. 
7.4 Statistical Analysis of Pharmacokinetic Data 
Descriptive statistics (mean, standard deviation, coefficient of variation  [CV%], 
geometric mean, geometric CV%, etc.) will be calculated for the PK parameters. No 
formal statistical analyses are planned.  
Specification of PK parameters for analysis; statistical level of significance to be used; 
procedures for accounting for missing, unused, or spurious data; procedures for reporting deviations from the original statistical plan; and selection of subjects to be included in the analyses population(s) , as applicable,  will be presented in the Clinical Study Report 
and/or SAP as appropriate.  
7.5 Statistical Analyses of Safety Data 
Descriptive statistics will be calculated for the safety parameters. No formal statistical 
analyses are planned.  
For change from baseline calculations, baseline will be defined as the last non -missing 
safety assessment (including any unscheduled assessments) prior to dose. 
Page 36 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 36 of 48 
 7.6 Data Handling and Record Keeping  
Any changes to information in the trial progress notes and  other source documents will be 
initialed and dated on the day the change is made by a clinical site staff member 
authorized to make the change. Changes will be made by striking a single line through 
erroneous data and clearly entering the correct data (e.g., wrong data right data). If the 
reason for the change is not apparent, a brief explanation for the change will be written adjacent to the change by the clinician.  
The Data Management Plan will be  approved by the Sponsor. 
Data will be  validated during data entry by the clinical site and verified by the study 
monitor. Data will then be reviewed by the data management group to resolve any outstanding issues. Listings will be  generated after the database is cleaned by Data 
Management  and will be  reviewed by the Covance scientific team. The CRF/electronic 
Case Report Form  (eCRF) and ancillary data will be  converted into final SAS datasets 
following Study Data Tabulation Model or client -provided specifications. The final 
datasets structure will be  verified using Pinnacle 21 OpenCDISC
®, while the dataset 
content will be  peer -reviewed by an independent programmer. 
The tables, figures, and listings (TFLs) will be  programmed per the final SAP. All TFLs 
will be  peer -reviewed by an independent programmer. In addition, draft TFL s will be  
reviewed by the Covance scientific team during the dry run and data review meetings.  
The peer -review will be  performed by independent programmers following the quality 
control process and programming checklists.  
7.7 Quality Control and Quality Assurance 
Quality control and quality assurance will be performed according to Covance standard operating procedures or per client request and as applicable according to the contract between Covance and the Sponsor. 
8 ADMINISTRATIVE ASPECTS  
8.1 Change in Protocol 
There will be no alterations in the protocol without agreement between the Sponsor and 
the Investigator. 
Page 37 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 37 of 48 
 There will be no alterations in the protocol affecting subject safety without the express 
written approval of the Sponsor, Investigator, and the Institutiona l Review Board ( IRB; 
see Form FDA 1572). 
8.2 Site Initiation Visit/Investigator Meeting  
Prior to the start of the clinical study, the representative(s) of the Sponsor will meet with the Investigator(s) and appropriate clinical staff to familiarize the Investig ator(s) and 
clinical staff with the materials necessary for conducting the clinical study.  
8.3 Disclosure 
All information provided regarding the study, as well as all information collected/documented during the study, will be regarded as confidential. The Inve stigator  
(or designee) agrees not to disclose such information in any way without prior written 
permission from the Sponsor. 
Any publication of the results, in part or in total ( e.g., articles in journals or newspapers, 
oral presentations, abstracts) by th e Investigator(s) or their representative(s), shall require 
prior notification and review, within a reasonable time frame, by the Sponsor, and cannot 
be made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the Sponsor’s intellectual property rights.  
8.4 Monitoring  
The Sponsor will designate a Sponsor’s Study Monitor who will be responsible for monitoring this clinical trial. The Sponsor’s Study Monitor will monitor the study conduct, proper CRF and source documentation completion and retention, and accurate study drug accountability. To this end, the Sponsor’s Study Monitor will visit the clinical  
site at suitable intervals and be in frequent contact through verbal and written communication. It is essential that the Sponsor’s Study Monitor has access to all documents (related to the study and the individual participants) at any time these are requested. In turn, the Sponsor’s Study Monitor will adhere to all requirements for subject confidentiality as outlined in the ICF. The Investigator  and Investigator ’s staff 
will be expected to cooperate with the Sponsor’s Study Monitor, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
Page 38 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 38 of 48 
 8.5 Institutional Review Board 
In accordance with US Title 21 CFR 56, the protocol, advertisement, ICF, and other 
information provided to subjects will be reviewed and approved by the IRB. The Sponsor 
will supply relevant material for the Investigator (or designee) to submit to the  IRB for 
the protocol’s review and approval. Verification of the IRB unconditional approval of the 
protocol and the written ICF statement will be transmitted to the Investigator  (or 
designee) . 
The IRB will be informed by the Investigator (or designee) of subse quent protocol 
amendments and of serious and unexpected AEs. Approval for protocol amendments will 
be transmitted in writing to the Investigator (or designee). If requested, the Investigator 
(or designee) will permit audits by the IRB and regulatory inspec tions by providing direct 
access to source data/documents.  
The Investigator (or designee)  will provide the IRB with progress reports at appropriate 
intervals (not to exceed 1 year) and a Study Progress Report following the completion, 
termination, or discontinuation of the Investigator ’s participation in the study.  
8.6 Informed Consent  
Written informed consent for the study will be obtained from all subjects before protocol-specific procedures are carried out. The ICF will be approved (along with the protocol) by the IRB and will be acceptable to the Sponsor. 
The Investigator (or designee) will explain the nature of the study and the action of the 
test product. The subjects will be informed that participation is voluntary and that they can withdraw from the study at any time. In accordance with 21 CFR 50, the informed consent process shall be documented by the use of a written ICF approved by the IRB 
and signed by the subject prior to protocol- specific procedures being performed.  
The subject will sign 2 copies of the ICF. One copy will be given to the subject , and the 
other will be maintained with the subject’s records.  
8.7 Records  
The results from data collected at Screening and during the study will be recorded in the 
subject’s CRF (paper or eCRF). To maintain confi dentiality, the subjects will be 
identified only by numbers. 
Page 39 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 39 of 48 
 The completed CRFs will be transferred to the Sponsor (or designee). Copies of each 
CRF will be retained by the Investigator  (or designee) . All source documents, records, 
and reports will be reta ined by the clinical  site in accordance with 21 CFR 312.62(c). 
All primary data, or copies thereof ( e.g., laboratory records, CRFs, data sheets, 
correspondence, photographs, and computer records), which are a result of the original observations and activities of the study and are necessary for the reconstruction and evaluation of any study report, will be re tained in the clinical  site archives.  
8.8 Reference to Declaration of Helsinki/Basic Principles  
The study procedures outlined in this protocol will be conducted in accordance with the US CFR  governing Protection of Human Subjects (21 CFR 50), Financial Disclos ure by 
Clinical Investigators (21 CFR 54), IRBs (21 CFR 56), Investigational New Drug Application (21 CFR 312), Applications for FDA Approval to Market a New Drug (21 CFR 314), and Radioactive Drugs For Certain Research Uses (21 CFR 361.1), as 
appropriate. As such, these sections of US Title 21 CFR, along with the applicable International Conference on Harmonisation Guidelines, are commonly known as Good Clinical Practices , which are consistent with the Declaration of Helsinki.  
8.9 Financing and Insurance  
Finan cing and insurance will be addressed in a separate agreement.  
Page 40 of 49
CoLucid Pharmaceuticals, Inc. 
Clinical Protocol 
Covance Study 8331469 
INVESTIGATOR AGREEMENT CONFIDENTIAL 
Protocol COL MIG-II 0 
I have read the foregoing protocol and agree to conduct the study as described herein. 
 Date 
 
Covance Clinical Research Unit, Inc. 
Finall.O: 23 January 2017 Page 40 of48 
Page 41 of 49
PPD
PPD
PPD
PPD
CoLucid Pharmaceuticals, Inc. 
Clinical Protocol 
Covance Study 8331469 
SPONSOR AGREEMENT CONFIDENTIAL 
Protocol COL :tv.IIG-110 
I have read the foregoing protocol and agree to conduct the study as described herein: 
 Date 
 
CoLucid Pharmaceuticals, Inc. 
Final 1.0: 23 January 2017 Page 41 of 48 
Page 42 of 49
PPD
PPD
PPD
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 42 of 48 
 REFERENCES  
1. Goadsby PJ, Lipton RB, Ferrari MD. M igraine -current understanding and 
treatment. N Engl J Med . 2002;346(4):257-270. 
2. Dodick DW, Lipton RB, Martin V, et al. Triptan Cardiovascular Safety Expert 
Panel. Consensus statement: cardiovascular safety profile of triptans (5- HT 
agonists) in the acute treatment of migraine. Headache . 2004;44:414-425. 
3. Potchoiba MJ and Oswald J. Covance 8332113. Dosimetry Calculations for [
14C]-Lasmiditan Base on Quantitative Whole-Body Autoradiographic Data in 
Rats.  Covance Laboratories , Inc.; Madison, Wisconsin; 2016. 
4. Gibaldi M, Perrier D. Pharmacokinetics. 2nd edition. New York, NY: Marcel 
Dekker Inc.; 1982. 
5. Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonisation; Guidelines on Structure and Content of Clinical Study Reports; Availability.  Federal Register. 
1996;61(138):37320-37343. 
Page 43 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 43 of 48 
 APPENDIX A - CLINICAL LABORATORY EVALUATIONS  
Clinical Chemistry Panel (Fasted):  Complete Blood Count : Urinalysis:  
Alanine aminotransferase  Hematocrit  Bilirubin  
Albumin  Hemoglobin  Color and appearance  
Alkaline phosphatase  Mean corpuscular hemoglobin  Glucose  
Aspartate aminotransferase  
Blood urea nitrogen Mean corpuscular hemoglobin 
concentration  Ketones  
Leukocyte  esterase  
Calcium  Mean corpuscular volume  Nitrite  
Chloride  Platelet count  Occult blood  
Cholesterol  Red blood cell (RBC) count  pH and specific gravity  
Creatinine  RBC distribution width  Protein  
Glucose  White blood cell (WBC) count  Urobilinogen  
Iron 
Phosphorus  
Potassium  
Sodium  WBC  differential  (absolute):  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils  Microscopic exam including 
bacteria, casts, crystals, 
epithelial cells, RBCs , and 
WBCs  (if protein, leukocyte 
esterase, nitrite, or blood is positive ) 
Total bilirubin    
Total protein    
Triglycerides    
Uric acid    
   
   
Drug Screen:  Other Tests:  Hormone panel – females 
only:  
Including but not limited to the 
following:  Hepatitis B surface antigen  
Hepatitis C virus antibody  Follicle -stimulating hormone 
(postmenopausal females only)  
Alcohol (ethanol ; via breathalyzer; 
at Check -in only ) 
Amphetamines  Human Immunodeficiency Virus 
antibody  Serum pregnancy test (human 
chorionic gonadotropin)  
Barbiturates  
Benzodiazepines    
Cannabinoids    
Cocaine (metabolite)    
Methadone    
Opiates    
Phencyclidine  
Cotinine    
Page 44 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 44 of 48 
 APPENDIX B - BLOOD S AMPLING S UMMARY  
Purpose  Maximum Blood Volume 
per Sample (mL)  Maximum Number of 
Blood Samples  Maximum Total 
Volume (mL)  
Serology  4 1 4 
Pharmacokinetic  and total 
radioactivity  sampling 10 23 230 
Metabolism sampling  10 7 70 
Clinical laboratory tests  8 4 32 
Pregnancy tests  4 2 8 
FSH tests  4 1 4 
Total    348 
Page 45 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 45 of 48 
 APPENDIX C - ADVERSE EVENTS  
1 ADVERSE EVENTS  
1.1 Definition of Adverse Events  
An adverse event ( AE; or adverse experience) is defined as any untoward medical 
occurrence experienced by a patient or healthy subject, whether or not considered drug 
related by the Investigator  (or designee). A treatment -emergent AE is an AE that is reported 
after a dose of st udy drug. 
 The following are all AEs : 
• unfavorable changes in general condition; 
• subjective or objective signs/symptoms; 
• concomitant diseases or accidents;  
• clinically relevant adverse changes in laboratory parameters 
observed in a subject during a clinical study.  
 
Adverse events  comprise all disturbances of general health status, subjective and 
objective disease symptoms (including laboratory abnormalities), and accidents observed in the context of a clinical trial, irrespective of a possible causal relationship with the administration of the trial substance. Events occurring in the framework of a clinical trial during drug-free and post-treatment periods, under placebo, or in a reference group receiving drug or nondrug therapy are also to be designated as AEs.  
1.2 Categorization of A dverse Events  
The severity of AEs will be categorized as follows:  
• MILD  = of little concern to the subject and/or of no clinical 
significance,  is not expected to affect the subject’s health or 
well-being ; 
• MODERATE  = discomforting enough to cause interferenc e with 
or change in usual activities, is likely to require medical intervention or close follow-up; 
• SEVERE  = incapacitating or causing inability to work or 
participate in many or all usual activities, is of concern to the subject or poses substantial risk to the subject’s health or 
Page 46 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 46 of 48 
 well-being, is likely to require medical intervention or close 
follow-up. 
 
The Investigator  (or designee)  will make a determination of the relationship of the AE to 
the study drug using a 2- category system according to the follow ing guidelines:  
• Reasonable Possibility  = a plausible temporal relationship exists 
between the AE onset and administration of the investigational product, and the AE cannot be readily explained by the subject’s clinical state or concomitant therapies.  
Furth ermore, the AE appears with some degree of certainty to be 
possibly related, based on the known therapeutic and pharmacologic actions or AE profile of the investigational product. In case of cessation or reduction of the dose, the AE may abate or resolve and it may reappear upon rechallenge.  
• No Reasonable Possibility = evidence exists that the AE has an 
etiology other than the investigational product and/or no plausible 
temporal relationship exists between the AE onset and administration of the investigatio nal product.  
For SAEs, an alternative causality must be provided (e.g., pre-existing condition, underlying disease, intercurrent illness, or concomitant medication).  
 An AE is associated with the use of the drug if there is a reasonable possibility that the experience may have been caused by the drug.  
 The following categories will be used for the action taken with the study drug for the AE: drug withdrawn, dose not changed, drug interrupted, unknown, and not applicable.  The following categories will be u sed for the outcome of the AE: resolved, resolved with 
sequelae, ongoing, fatal, and unknown. 
1.3 Pregnancy  
As information is available, a pregnancy diagnosed during the study will be reported 
immediately to the Investigator  (or designee) or Sponsor, including pregnancy in female 
partners of male subjects. The pregnancy may be followed to term or outcome and this outcome may be reported to the Sponsor. Pregnancy, in and of itself, is not regarded as an 
Page 47 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 47 of 48 
 AE or serious AE ( SAE ) unless the birth results in a congenital anomaly/birth defect or 
there is suspicion that the study medication may have interfered with the effectiveness of 
a contraceptive medication or method. 
1.4 Definition of Serious Adverse Events  
An SAE (by Food and Drug Administration [ FDA ] definition) is any adverse drug 
experience occurring at any dose that results in any of the following outcomes: 
• death;  
• a life -threatening adverse drug experience (i.e. , places the subject, 
in the view of the I nvestigator  (or designee) , at immediate risk o f 
death);  
• inpatient hospitalization or prolongation of existing hospitalization; 
• a persistent or significant disability/incapacity;  
• a congenital anomaly/birth defect;  
• important medical event that may require medical or surgical 
intervention to prevent one of the above outcomes. 
 
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the patient or subject and may require me dical or surgical 
intervention to prevent one of the outcomes listed in this definition. All SAEs must be collected that occur after the subject signs the Informed Consent Form. 
1.5 Unexpected Adverse Drug Experience 
An unexpected adverse drug experience is any adverse drug experience, the specificity or 
severity of which is not consistent with the current Investigator Brochure (IB) or, if an IB is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended.  
1.6 Reporting  
Food and Drug Administration- reportable AEs are AEs that are associated with the use of 
the drug and are serious and unexpected. Food and Drug Administra tion-reportable AEs 
will be reported by the clinical site to the Sponsor , Medical Monitor assigned by the 
Sponsor, and the responsible Institutional Review Board (IRB). 
Page 48 of 49
CoLucid Pharmaceuticals, Inc.  
Clinical Protocol  
Covance Study 8331469  CONFIDENTIAL  
Protocol COL MIG -110 
 
 
Final 1.0: 23 January 2017  Page 48 of 48 
 The Sponsor and Medical Monitor will be notified in writing ( e.g., facsimile) within 
24 hours of when an AE that is potentially FDA -reportable is first recognized or reported.  
 
Subsequently, a written confirmation or summary of the AE (using FDA Form 3500A, or equivalent) will be sent to the Sponsor within 3 working days of the original notification. (Instructions for completion of FDA Form 3500A may be obtained from the FDA website at www.fda.gov/medwatch/how.htm.).  The IRB will be not ified of any  FDA- reportable AE within the timeframe required by the 
IRB. The IRB Serious and Unexpected Adverse Experience Submission Form will be 
complete d and submit ted with the copy of the written confirmation or summary of the 
AE.  
 
Page 49 of 49